Search

Displaying results 4121 - 4130 of 10000 in total
  1. Indication

    Dyspepsia

    go.drugbank.com/conditions/DBCOND0004526
    Drugs: Alginic acid · Almasilate · Aluminium glycinate · Aluminium phosphate · Aluminum hydroxide · Anise oil +27 more
    Synonyms: Non Ulcer Dyspepsia, Dyspepsia, NOS
  2. Drug

    CZEN 002

    go.drugbank.com/drugs/DB05479
    Experimental

    The antimicrobial activity of CZEN-002 is unique in that it does not depend on direct damage to the microbial membrane. … CZEN-002 is a novel, non-azole anti-fungal synthetic octapeptide, derived from alpha-Melanocyte-Stimulating Hormone (a-MSH). CZEN-002 modulates inflammatory and immune responses.

  3. Drug

    (+)-menthol

    go.drugbank.com/drugs/DB11344
    Approved

    Mixtures: Ay Bendito - Pain Relief, Ay Bendito - Thermoactive
  4. Drug

    Flurbiprofen axetil

    go.drugbank.com/drugs/DB14938
    Investigational

    Flurbiprofen axetil is under investigation in clinical trial NCT02043366 (Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients).

    Categories: Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal
  5. Drug

    Mirikizumab

    go.drugbank.com/drugs/DB14910
    ApprovedInvestigational

    Mirikizumab is a monoclonal antibody developed by Eli Lilly intended to treat ulcerative colitis. … [L46252] It was officially approved in the EU in May 2023[L48656] and Canada in July 2023[L48661], and was eventually approved in the US in October 2023[L48651] for the treatment of adult patients with

  6. Drug

    Levotofisopam

    go.drugbank.com/drugs/DB19073
    Investigational

    Levotofisopam is under investigation in clinical trial NCT01519687 (Study of Levotofisopam 50 Mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout).

  7. Drug

    Ibudilast

    go.drugbank.com/drugs/DB05266
    Investigational

    (codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan. … Ibudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume

  8. Drug

    Meningococcal polysaccharide vaccine group A

    go.drugbank.com/drugs/DB13889
    ApprovedInvestigational

    It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup A. … *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia.

  9. Drug

    Meningococcal polysaccharide vaccine group C

    go.drugbank.com/drugs/DB13890
    ApprovedInvestigational

    It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C. … *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia.

  10. Drug

    Dengue virus serotype 1

    go.drugbank.com/drugs/DB22664
    Approved

    [A274008] It is one of four serotypes covered by Qdenga, a live, attenuated, tetravalent vaccine used for the prevention of dengue disease.